You are here
Patients Given Choice to Switch to Lenalidomide Treatment Arm in Phase 3 SWOG Trial
According to SWOG, the 198 patients enrolled in the trial, prior to the closure, are sufficient to provide data analysis and evaluate the primary endpoint of progression-free survival (PFS) in the two arms of the trial. Data analysis is ongoing and results will be presented and released in the usual fashion.
Revlimid(lenalidomide) is approved by the U.S. Food and Drug Administration for use as a treatment in combination with standard-dose dexamethasone for patients with multiple myeloma who have received at least one prior therapy. Revlimid is approved for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Revlimid recently received a positive opinion from the European Medicines Agency (EMEA) for use in combination with dexamethasone as a treatment for patients with multiple myeloma who have received at least one prior therapy.
Source: Celgene Corporation